| Project/Area Number |
26462189
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Kyorin University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NAGANE Motoo 杏林大学, 医学部, 教授 (60327468)
|
|---|
| Research Collaborator |
SASAKI Nobuyoshi
LEE Jeunghun
SHIMIZU Saki
SUZUKI Kaori
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 脳腫瘍 / 中枢神経系悪性リンパ腫 / 遺伝子異常 / MGMT / MYD88 / MMSE / 予後因子 / mismatch repair蛋白 / Bcl6 / 全エクソンシークエンス |
|---|
| Outline of Final Research Achievements |
Primary central nervous system lymphoma (PCNSL) is one of the deadly malignant brain tumors, but exhibits a high response to combination immunochemotherapy with rituximab, methotrexate, procarbazine, vincristine and cytarabine (R-MPV-A). We analyzed 32 patients with newly diagnosed PCNSL composed of diffuse large B cell lymphoma (DLBCL) for potential genetic alterations as well as prognostic factors for progression-free survival (PFS). We found MYD88 mutations in 70% of patients which is much higher than in those with systemic DLBCL, while MGMT promoter was methylated in 60% of cases. Factors associated with longer PFS are age<70 years (p=0.059), single lesion (p=0.010), methylated MGMT promoter (p=0.056), and MMSE score ≧ 24 (p=0.025), but MYD88 mutations did not affect outcome (p=0.186, rather mutated MYD88 patients tended to live longer). These results suggest that methylated MGMT and high baseline MMSE score might predict higher benefit and better outcome with R-MPV-A treatment.
|
